PCM
AKBA icon

Penserra Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Penserra Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,995
Closed -$11K – 1352
2021
Q3 		$11K Buy
3,995
+350
+10% +$999 ﹤0.01% 1342
2021
Q2 		$13K Buy
3,645
+165
+5% +$555 ﹤0.01% 1249
2021
Q1 		$11K Buy
3,480
+160
+5% +$576 ﹤0.01% 1019
2020
Q4 		$9K Buy
3,320
+2,100
+172% +$6.13K ﹤0.01% 930
2020
Q3 		$3K Buy
+1,220
New +$10.7K ﹤0.01% 880

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Penserra Capital Management's AKBA Position: Q4 2021 in Review

Penserra Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 3,995 shares — an estimated $11K sold.

Penserra Capital Management first reported a position in AKBA in Q3 2020 and held it in 5 quarters. The position peaked at $13K in Q2 2021. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

  • Penserra Capital Management reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 3,995 Akebia Therapeutics shares in Q4 2021, an estimated $11K.
  • Penserra Capital Management first reported a position in Akebia Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Akebia Therapeutics position peaked at $13K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.